The patent is issued for the AspirinWorks Test Kit, which measures thromboxane metabolites in urine to evaluate aspirin effect in apparently healthy individuals.
The composition-of-matter claims provide intellectual property coverage for the monoclonal antibody that recognizes thromboxane metabolites, the company said.
Corgenix president and chief executive officer Douglass Simpson said, "By further protecting the AspirinWorks Test we’re strengthening our intellectual property portfolio and enhancing our competitive position in the clinical testing market."
In 2010, Corgenix was issued a US patent related to the AspirinWorks Test’s ability to depict true levels of circulating thromboxane metabolites, chemicals that activate blood platelets and cause them to stick together.